Robin joined Brandon Capital in 2021.
With over 30 years of experience in drug discovery, Robin is a widely regarded industry veteran and thought leader in innovative/novel drug discovery.
He has held senior roles in Glaxo Wellcome, GSK and Astex Therapeutics. At GSK, he was senior Vice President of Drug Design and Selection and held global responsibility for GSK’s small molecule and biopharm drug discovery platforms. At Astex Therapeutics, Robin was VP Drug Discovery, with responsibility for its internal and partnered discovery programmes.
Robin has experiences in innovative approaches to small molecule drug discovery, specifically fragment-based discovery, DNA encoded libraries, covalent drug discovery, protein degradation and the integration of chemical technologies into structure and predictive modelling-based drug design.
During his career, Robin has contributed to numerous discovery programs that have progressed into the clinic, two of which went on to become launched drugs within oncology. He has co-authored and published 50 papers and patents.
Robin obtained his PhD in Chemistry from Northwestern University, Illinois and a BSc from Imperial College, London.
